NO911602L - Immunogent aktive fraksjoner av borrelia burgdorferi. - Google Patents

Immunogent aktive fraksjoner av borrelia burgdorferi.

Info

Publication number
NO911602L
NO911602L NO91911602A NO911602A NO911602L NO 911602 L NO911602 L NO 911602L NO 91911602 A NO91911602 A NO 91911602A NO 911602 A NO911602 A NO 911602A NO 911602 L NO911602 L NO 911602L
Authority
NO
Norway
Prior art keywords
burgdorferi
fractions
cells
active fractions
sera
Prior art date
Application number
NO91911602A
Other languages
English (en)
Norwegian (no)
Other versions
NO911602D0 (no
Inventor
Sven Bergstroem
Alan G Barbour
Louis A Magnarelli
Original Assignee
Symbicom Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8146053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO911602(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Symbicom Ab filed Critical Symbicom Ab
Publication of NO911602D0 publication Critical patent/NO911602D0/no
Publication of NO911602L publication Critical patent/NO911602L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1207—Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO91911602A 1988-10-24 1991-04-23 Immunogent aktive fraksjoner av borrelia burgdorferi. NO911602L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK590288A DK590288D0 (da) 1988-10-24 1988-10-24 Kemiske forbindelser
PCT/DK1989/000248 WO1990004411A1 (en) 1988-10-24 1989-10-24 Immunogenically active fractions of borrelia burgdorferi

Publications (2)

Publication Number Publication Date
NO911602D0 NO911602D0 (no) 1991-04-23
NO911602L true NO911602L (no) 1991-06-24

Family

ID=8146053

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91911602A NO911602L (no) 1988-10-24 1991-04-23 Immunogent aktive fraksjoner av borrelia burgdorferi.

Country Status (10)

Country Link
US (6) US5523089A (fi)
EP (4) EP0565208B1 (fi)
AT (3) ATE432988T1 (fi)
AU (1) AU639667B2 (fi)
CA (1) CA2001328C (fi)
DE (4) DE68929369T2 (fi)
DK (3) DK590288D0 (fi)
FI (1) FI112366B (fi)
NO (1) NO911602L (fi)
WO (1) WO1990004411A1 (fi)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US6054296A (en) 1988-10-24 2000-04-25 Symbicom Ab 66 kDa antigen from Borrelia
US6300101B1 (en) * 1988-10-24 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions including a 13kD B. burgdorferi protein
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
ZA907419B (en) * 1989-09-19 1991-07-31 Max Planck Gesellschaft Vaccine against lyme disease
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5470712A (en) * 1990-03-05 1995-11-28 Us Health Antigenic proteins of Borrelia burgdorferi
JPH06501382A (ja) 1990-06-15 1994-02-17 エール ユニバーシティ ライム病の予防および診断に用いる組成物および方法
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US5436000A (en) * 1991-01-11 1995-07-25 University Of Texas System Flagella-less borrelia
CA2110920A1 (en) * 1991-06-13 1992-12-23 Sinfu Tzeng Assay for the detection of specific ligands
US5324630A (en) * 1991-06-28 1994-06-28 The Regents Of The University Of California Methods and compositions for diagnosing lyme disease
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
JPH07501687A (ja) * 1991-08-15 1995-02-23 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） ボレリア・ブルグドルフェリのサブグループのｏｓｐ　ａ　蛋白、それをコードしている遺伝子およびワクチン
PT100980B (pt) * 1991-10-18 1999-07-30 Connaught Lab Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao
AU2903892A (en) * 1991-10-22 1993-05-21 Symbicom Aktiebolag Improvement in (borrelia burgdorferi) diagnosis and prophylaxis
US5618533A (en) * 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5308753A (en) * 1992-02-20 1994-05-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for purifying and detecting IGM antibodies
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
BE1006728A3 (fr) * 1993-02-19 1994-11-29 Wallone Region Sondes d'acides nucleiques specifiques au spirochete borrelia burgdorferi.
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US6716591B1 (en) 1993-07-30 2004-04-06 Yale University B. burgdorferi polypeptides
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
EP0757556B1 (en) * 1994-04-11 2006-06-14 Wyeth Holdings Corporation Borrelia burgdorferi bacterin
US6087097A (en) * 1994-05-12 2000-07-11 Mayo Foundation For Medical Education And Research PCR detection of Borrelia burgdorferi
US6214355B1 (en) 1995-04-24 2001-04-10 Texas A & M University System DbpA compositions
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
US6248517B1 (en) 1995-04-24 2001-06-19 The Texas A & M University System Decorin binding protein compositions and methods of use
US6312907B1 (en) 1995-04-24 2001-11-06 The Texas A & M University System DbpA compositions and methods of use
AU6028396A (en) * 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
US6251405B1 (en) * 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
ZA964896B (en) 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
US6045804A (en) * 1996-03-07 2000-04-04 Mayo Foundation For Medical Educational Research Method for detecting B. burgdorferi infection
EP0915977A1 (en) * 1996-05-08 1999-05-19 Yale University B. burgdorferi polypeptides expressed in vivo
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
DE19632862B4 (de) * 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
AU8151898A (en) * 1997-06-20 1999-01-04 Human Genome Sciences, Inc. Lyme disease vaccines
US6902893B1 (en) 1997-06-20 2005-06-07 Gil H. Choi Lyme disease vaccines
DK1012181T3 (da) * 1997-06-30 2007-01-02 Univ Tulane Overfladeantigener og proteiner, der er nyttige i præparater til diagnose og forebyggelse af Lymes sygdom
WO1999012960A2 (en) * 1997-09-10 1999-03-18 Symbicom Ab P13 ANTIGENS FROM $i(BORRELIA)
US6610838B1 (en) 1997-09-10 2003-08-26 Symbicom Aktiebolag P13 antigens from Borrelia
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
GB9811219D0 (en) * 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
US6475492B1 (en) 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
US6592875B1 (en) * 1999-06-21 2003-07-15 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
US6689364B2 (en) * 2000-03-21 2004-02-10 Tufts University Borrelia burgdorferi polypeptides and uses thereof
WO2001092870A2 (de) * 2000-06-02 2001-12-06 Zeptosens Ag Kit und verfahren zur multianalytbestimmung
WO2002016421A2 (en) 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
US20040033623A1 (en) * 2002-08-16 2004-02-19 Igenex, Inc. Assay for detection of antigen in bodily fluid
US20050058661A1 (en) * 2002-10-18 2005-03-17 Sykes Kathryn F. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus Borrelia
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
EP2030979A1 (en) * 2003-04-02 2009-03-04 The Government of the United States of America as Represented by The Department of Health and Human Services Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
US20060051060A1 (en) * 2003-07-03 2006-03-09 Henry Dorovanessian Method and system for digitally recording broadcast content
WO2006026248A1 (en) 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
US20060281139A1 (en) * 2005-05-23 2006-12-14 Viramed Biotech Ag Carrier and method for the detection of anti-borrelia antibodies and test kit for use in the diagnosis of Lyme borreliosis infections
US7663212B2 (en) 2006-03-21 2010-02-16 Infineon Technologies Ag Electronic component having exposed surfaces
US7541681B2 (en) * 2006-05-04 2009-06-02 Infineon Technologies Ag Interconnection structure, electronic component and method of manufacturing the same
BRPI0719360B1 (pt) 2006-11-03 2016-09-06 Intervet Int Bv vacina da doença de lyme canina, e, uso de organismos de uma genoespécie de borrelia
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2009126816A1 (en) * 2008-04-09 2009-10-15 Ventria Bioscience Production of ospa for lyme disease control
JP5721620B2 (ja) 2008-05-02 2015-05-20 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ 免疫応答を刺激するための作製物および方法
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
EP2545071A2 (en) 2010-03-09 2013-01-16 Maksyutov, Amir Polyepitope constructs and methods for their preparation and use
EP3705133B1 (en) 2010-05-14 2024-06-26 Baxalta Incorporated Ospa chimeras and use thereof in vaccines
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
RU2013118647A (ru) 2010-09-27 2014-11-10 Корнелл Юниверсити Способы диагностики болезни лайма
WO2012047970A1 (en) * 2010-10-05 2012-04-12 Board Of Trustees Of Michigan State University Regulatory factors controlling oil biosynthesis in microalgae and their use
JP2015524802A (ja) 2012-07-27 2015-08-27 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ キメラｏｓｐａ分子を含む組成物およびその使用方法
US10669567B2 (en) 2015-02-17 2020-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High sensitivity method for early Lyme disease detection
EA039370B1 (ru) 2016-04-14 2022-01-19 Мериал, Инк. Иммуногенная многодозовая композиция, содержащая антимикробный полиамидный консервант
WO2018227109A1 (en) 2017-06-08 2018-12-13 Colorado State University Research Foundation Differentiation of lyme disease and southern tick-associated rash illness
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
KR20250035053A (ko) 2022-06-07 2025-03-11 리제너론 파아마슈티컬스, 인크. T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US4888276A (en) 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) * 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
DE4015911A1 (de) 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit

Also Published As

Publication number Publication date
EP0711563A1 (en) 1996-05-15
DE68929550D1 (de) 2007-03-08
DK75091A (da) 1991-06-12
DK200401413A (da) 2004-09-17
DK590288D0 (da) 1988-10-24
DE68929369T2 (de) 2002-09-26
EP1092774A2 (en) 2001-04-18
DE68929369D1 (de) 2002-03-14
DE68929550T2 (de) 2007-12-06
ATE212376T1 (de) 2002-02-15
US5523089A (en) 1996-06-04
EP1092774A3 (en) 2001-04-25
CA2001328C (en) 2005-12-13
US6203798B1 (en) 2001-03-20
AU639667B2 (en) 1993-08-05
CA2001328A1 (en) 1991-04-24
NO911602D0 (no) 1991-04-23
DE68927891D1 (de) 1997-04-24
ATE432988T1 (de) 2009-06-15
DK75091D0 (da) 1991-04-23
US5688512A (en) 1997-11-18
EP0565208A1 (en) 1993-10-13
EP0565208B1 (en) 2002-01-23
EP0445135A1 (en) 1991-09-11
EP1092774B1 (en) 2009-06-03
US5582990A (en) 1996-12-10
FI911964A0 (fi) 1991-04-23
AU4495389A (en) 1990-05-14
US6183986B1 (en) 2001-02-06
WO1990004411A1 (en) 1990-05-03
EP0445135B1 (en) 1997-03-19
FI112366B (fi) 2003-11-28
DK175844B1 (da) 2005-03-29
ATE150318T1 (de) 1997-04-15
DE68927891T2 (de) 1997-10-02
EP0711563B1 (en) 2007-01-17
DE68929565D1 (de) 2009-07-16
US6083722A (en) 2000-07-04

Similar Documents

Publication Publication Date Title
NO911602L (no) Immunogent aktive fraksjoner av borrelia burgdorferi.
DE3165623D1 (en) Composition for therapeutic or diagnostic use
Kalish et al. Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in Lyme disease
Miller et al. Temporal Analysis of Borrelia burgdorferi Erp Protein Expression throughout the Mammal-Tick InfectiousCycle
Hefty et al. Regulation of OspE-related, OspF-related, and Elp lipoproteins of Borrelia burgdorferi strain 297 by mammalian host-specific signals
Cullen et al. Global analysis of outer membrane proteins from Leptospira interrogans serovar Lai
US9376472B2 (en) Polyvalent chimeric OspC vaccinogen and diagnostic antigen
DE69232956D1 (de) Verbesserungen der diagnose und der prophylaxe von borrelia burgdorferi
Luft et al. Immunologic and structural characterization of the dominant 66-to 73-kDa antigens of Borrelia burgdorferi
NO20070618L (no) Forbindelser og fremgangsmater for immunterapi og diagnose av tuberkulose.
Porcella et al. Variable tick protein in two genomic groups of the relapsing fever spirochete Borrelia hermsii in western North America
McAtee et al. Characterization of a Helicobacter pylori vaccine candidate by proteome techniques
EP1012181B1 (en) Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
Noppa et al. P13, an integral membrane protein of Borrelia burgdorferi, is C-terminally processed and contains surface-exposed domains
DK0479948T3 (da) Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder
WO1997042221A1 (en) Novel osp-c derived peptide fragments
PT726955E (pt) Proteinas quimericas compreendendo polipeptidos borrelia: suas utilizacoes
DE69531345D1 (de) Rekombinant pgp3, verfahren zu dessen herstellung, und dessen verwendung in der diagnose und therapie
EP3029073B1 (en) Polyvalent chimeric ospc vaccinogen and diagnostic antigen
US20030138866A1 (en) Novel Osp-C derived peptide fragments
Perng et al. Further characterization of a potent immunogen and the chromosomal gene encoding it in the Lyme disease agent, Borrelia burgdorferi
Jiang et al. Mapping the major antigenic domains of the native flagellar antigen of Borrelia burgdorferi
Jones et al. Strong IgG antibody responses to Borrelia burgdorferi glycolipids in patients with Lyme arthritis, a late manifestation of the infection
AR014647A1 (es) Un polipeptido lipl32 de proteina de membrana externa leptoespiral, un polinucleotido aislado, un vector de expresion, una celula huesped, un metodopara producir dicho polipeptido lipl32, uso de dicho polipeptido para la manufactura de un medicamento, un anticuerpo, una composicion farmaceutica,
CN101374858A (zh) 多价嵌合ospc疫苗原及诊断抗原